Maarten J. IJzerman
YOU?
Author Swipe
View article: Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia
Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia Open
This Australian single-arm study demonstrated that pre-emptive PGx screening prevents severe, fatal FP-related toxicities and hospitalisations and is likely to be cost effective. Our findings suggest the value of PGx screening and warrant …
View article: Implementation of whole genome sequencing in cancer management: modelling and sensitivity analysis using system dynamics
Implementation of whole genome sequencing in cancer management: modelling and sensitivity analysis using system dynamics Open
Precision oncology using biomarkers and genomic testing facilitates individualised diagnosis and consequently treatment for cancer patients. Standard of Care is conducted through assays of biomarkers for treatment selection. However, Whole…
View article: Carbon footprint and staff demands of surgery and chemoradiation for muscle‐invasive bladder cancer
Carbon footprint and staff demands of surgery and chemoradiation for muscle‐invasive bladder cancer Open
Objective To calculate the environmental and labour impact of two complete care pathways for patients with muscle‐invasive bladder cancer (MIBC) with similar oncological outcomes: radical cystectomy (RC) and chemoradiation (CRT), by quanti…
View article: Travel distance and potential disparities in palliative radiotherapy access for cancer patients in Victoria, Australia
Travel distance and potential disparities in palliative radiotherapy access for cancer patients in Victoria, Australia Open
Background Palliative radiotherapy (PRT) is crucial for improving quality of life in patients with advanced-staged cancer. This large data analysis investigates the travel distances and potential disparities in PRT access especially focusi…
View article: Clinician survey on the value of risk prediction for immune-related adverse events induced by immune checkpoint inhibitors
Clinician survey on the value of risk prediction for immune-related adverse events induced by immune checkpoint inhibitors Open
Introduction Identification of risk factors to predict immune-related adverse events (irAE) is a growing research area. This baseline study explores which factors oncology clinicians consider, perspectives on the value of risk prediction, …
View article: Operational and path dependencies impede the feasibility of hospital-based production of individually engineered drugs
Operational and path dependencies impede the feasibility of hospital-based production of individually engineered drugs Open
Hospital-based production of gene therapies is a promising new approach for patients with high unmet medical needs, particularly those with rare diseases. However, operational and technical path dependencies (e.g. supply of materials, prod…
View article: Development and Qualitative Evaluation of a Decision Support Tool for Withdrawal of Biologic Therapy in Nonsystemic Juvenile Idiopathic Arthritis
Development and Qualitative Evaluation of a Decision Support Tool for Withdrawal of Biologic Therapy in Nonsystemic Juvenile Idiopathic Arthritis Open
Introduction. Limited evidence guides pediatric rheumatologists on when to withdraw biologic therapy in children with juvenile idiopathic arthritis, resulting in wide variation in clinical practice. This study aimed to develop and evaluate…
View article: NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines
NANOSPRESSO: toward personalized, locally produced nucleic acid nanomedicines Open
The NANOSPRESSO project is a pioneering response to the complex challenge of treating orphan diseases, which, despite affecting millions of people globally, have only scant therapeutic options. This initiative represents a paradigm shift b…
View article: Understanding experiences of optimal survivorship care: findings from a population-based study of cancer survivors
Understanding experiences of optimal survivorship care: findings from a population-based study of cancer survivors Open
Background Multiple frameworks describing optimal cancer survivorship care recommend the development of systems to monitor delivery of quality care. This study reports the experiences of cancer survivorship care in Australia and examines a…
View article: Factors associated with diagnostic and treatment intervals in colorectal cancer: A linked data study
Factors associated with diagnostic and treatment intervals in colorectal cancer: A linked data study Open
This research aimed to assess the length of intervals before diagnosis and treatment for colorectal cancer in Australia using linked datasets, and to determine any factors associated with interval length. A colorectal cancer clinical regis…
View article: External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinoma
External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinoma Open
Background Immune checkpoint inhibitors (ICIs) provide a significant survival benefit in non-small cell lung cancer (NSCLC) patients; however, accurately predicting which patients will benefit remains a challenge. As previously shown, the …
View article: Toward value-based care using cost mining: cost aggregation and visualization across the entire colorectal cancer patient pathway
Toward value-based care using cost mining: cost aggregation and visualization across the entire colorectal cancer patient pathway Open
Background The aim of this study is to develop a method we call “cost mining” to unravel cost variation and identify cost drivers by modelling integrated patient pathways from primary care to the palliative care setting. This approach fill…
View article: Analysis of risk factors for immune-related adverse events induced by immune checkpoint inhibitor treatment in cancer: A comprehensive systematic review
Analysis of risk factors for immune-related adverse events induced by immune checkpoint inhibitor treatment in cancer: A comprehensive systematic review Open
This systematic review provides a comprehensive overview of evidence on irAE risk factors across a large patient population. Studies were heterogeneous resulting from variations in design, sample size and analysis method, and lack generali…
View article: Pharmacogenetic‐guided dosing for fluoropyrimidine (<i>DPYD</i>) and irinotecan (<i>UGT1A1*28</i>) chemotherapies for patients with cancer (<scp>PACIFIC</scp>‐<scp>PGx</scp>): A multicenter clinical trial
Pharmacogenetic‐guided dosing for fluoropyrimidine (<i>DPYD</i>) and irinotecan (<i>UGT1A1*28</i>) chemotherapies for patients with cancer (<span>PACIFIC</span>‐<span>PGx</span>): A multicenter clinical trial Open
PACIFIC‐PGx evaluated the feasibility of implementing pharmacogenetics (PGx) screening in Australia and the impact of DPYD/UGT1A1 genotype‐guided dosing on severe fluoropyrimidine (FP) and irinotecan‐related toxicities and hospitalizations…
View article: Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review Open
Background Immune-related adverse events (irAE) induced by immune checkpoint inhibitors (ICI) are a treatment-limiting barrier. There are few large-scale studies that estimate irAE prevalence. This paper presents a systematic review that r…
View article: Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making: A Good Practices Report of an ISPOR Task Force
Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making: A Good Practices Report of an ISPOR Task Force Open
Healthcare decision making, including regulatory and reimbursement decisions, is based on uncertain assessments of clinical and economic value. This arises from the evidence supporting those assessments being uncertain, incomplete, or even…
View article: Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing
Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing Open
The clinical utility and outcomes of MCED testing for screening and early detection still lack comprehensive evidence. Nonetheless, this simulation model facilitates a thorough analysis of MCED tests within the Australian healthcare contex…
View article: Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients
Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients Open
Payers commonly emphasize acceptable cost-effectiveness, but strong clinical evidence for many variants and comparable costs to standard tests are likely to drive positive reimbursement decisions for WGS.
View article: Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia
Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia Open
PRIMCAT-CRC is a versatile tool that can be used to estimate the eligible patient populations for novel cancer therapies, thereby reducing uncertainty for policymakers in decisions to publicly reimburse new treatments.
View article: Health-related quality of life in rural cancer survivors compared with their urban counterparts: a systematic review
Health-related quality of life in rural cancer survivors compared with their urban counterparts: a systematic review Open
Purpose We conducted a systematic review to describe health-related quality of life (HRQOL) in rural cancer survivors (RCS), and compare HRQOL between RCS and urban cancer survivors (UCS). Method We searched Medline, Embase, CINAHL Plus, a…
View article: Paving the path for implementation of clinical genomic sequencing globally: Are we ready?
Paving the path for implementation of clinical genomic sequencing globally: Are we ready? Open
Despite the emerging evidence in recent years, successful implementation of clinical genomic sequencing (CGS) remains limited and is challenged by a range of barriers. These include a lack of standardized practices, limited economic assess…
View article: Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis
Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis Open
Background: This study explores the potential benefits of neoadjuvant chemotherapy in borderline resectable (BR) pancreatic adenocarcinoma. Despite neoadjuvant treatment (NAT) increasingly being utilised, uncertainty remains as to the opti…
View article: Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework
Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework Open
Background: Advances in targeted therapy development and tumor sequencing technology are reclassifying cancers into smaller biomarker-defined diseases. Randomized controlled trials (RCTs) are often impractical in rare diseases, leading to …
View article: Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis
Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis Open
Objective To quantify differences in hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors (TNFi) in JIA patients. Methods This was a retrospective analysis of prosp…